Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
Teva Pharmaceutical (TEVA) Stock Price & Analysis
6,536 Followers
TEVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.42 - $17.69
Previous Close$16.25
Volume18.72M
Average Volume (3M)9.90M
Market Cap
$18.64B
Enterprise Value$36.18B
Total Cash (Recent Filing)$3.23B
Total Debt (Recent Filing)$20.15B
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 07, 2024EPS Estimate
$0.56Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding1,132,640,597
10 Day Avg. Volume8,596,072
30 Day Avg. Volume9,902,596
Standard Deviation0.12
R-Squared0.17
Alpha0.00655
Financial Highlights & Ratios
Price to Book (P/B)-1.28
Price to Sales (P/S)1.21
Price to Cash Flow (P/CF)4.10
P/FCF Ratio3.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.28
Enterprise Value/Gross Profit4.73
Enterprise Value/Ebitda35.82
Forecast
1Y Price Target
$19.71Price Target Upside20.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Teva Pharmaceutical News
Bulls Say, Bears Say
Bulls Say
Market ShareIncreasing confidence that the partnership with Alvotech can capture significant market share in upcoming launches.
Product DevelopmentOlanzapine LAI completes Phase 3 dosing with no PDSS, which could lead to approval and a significant revenue opportunity.
Revenue GrowthTEVA has a profit-sharing arrangement on high-value biosimilars, including Stelara and Simponi, which are expected to generate significant revenue.
Bears Say
Business PerformanceTEVA's North America generics business has underperformed expectations, and biosimilars are unlikely to replace lost gRevlimid sales in 2026+.
Financial PerformanceGross margins across TEVA's business have come in below expectations over the past year.
Market ExpectationsExpectations for biosimilars have increased despite challenging market fundamentals and still anemic Gx market growth.
---
Ownership Overview
0.66% Insiders
16.15% Mutual Funds
2.79% Other Institutional Investors
80.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $7.42 and its highest was $17.69 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Currently, no data Available
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Aug 07, 2024 which is in 36 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on May 08, 2024. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.514 by -$0.034.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is $0.56.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,132,592,400 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.48 in its last earnings report, missing expectations of $0.514. Following the earnings report the stock price went up 12.832%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Among the largest hedge funds holding Teva Pharmaceutical’s share is Slate Path Capital LP. It holds Teva Pharmaceutical’s shares valued at 380M.
---
Teva Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.71 (20.62% Upside)
$19.71 (20.62% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 90%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.66%
12-Months-Change
Fundamentals
Return on Equity
-6.08%
Trailing 12-Months
Asset Growth
-1.57%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
---
TEVA Company Deck
---
TEVA Earnings Call
Q1 2024
0:00 / 0:00
---
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
TEVA Stock 12 Month Forecast
Average Price Target
$19.71
▲(20.62% Upside)
Technical Analysis
Best Analysts Covering TEVA
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+27.37%
reiterated a buy rating 7 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +27.37% per trade.
---